Plain-English translation of NCT07292012 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing mirikizumab, a new biologic medication designed to reduce deep inflammation in Crohn's disease by targeting a specific part of the immune system. Researchers want to see if this medication can help heal the innermost layers of the gut lining, which is what 'transmural healing' means. This is a Phase 4 study, meaning the medication is already approved, but doctors want to learn more about how well it works for this specific goal.
Many people with Crohn's disease have inflammation that goes through all the layers of their intestinal wall, which can lead to serious complications. Researchers want to know if this medication can achieve deep healing in the gut, which might prevent complications and improve quality of life.
You likely qualify if…
You likely don't qualify if…
You would receive three intravenous infusions (IV treatments) of the medication at the clinic over the first 8 weeks (at weeks 0, 4, and 8). After that, if the medication is working for you, you would switch to self-injecting the medication under your skin every 4 weeks. You would have regular clinic visits and imaging tests (MRI scans) to see if the deep inflammation is healing. The study involves about 75 participants total.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
France